In Silico-Guided Sequence Modification of Epitopes in Cancer Vaccine Development

Hoo, Winfrey Pui Yee; Siak, Pui Yan; In, Lionel Lian Aun

doi:10.1007/978-1-0716-0389-5_10

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In silico prediction, while an indispensable tool for modern studies on T cell stimulation, does not always predict the right peptide that would be able to bind to the MHC molecule's peptide binding groove, not to mention, stimulate the T cells needed to fight infection or disease, especially when it comes to MHC Class II molecules [10]. The following results, obtained with recombinant MHC molecules, can be used in the future to determine the nature of the T cell immune responses to SARS-CoV-2 without questioning what viral peptide sequences can be presented by which MHC molecules.…”

Section: Resultsmentioning

confidence: 99%

Assessment of SARS-CoV-2 Specific CD4(+) and CD8 (+) T Cell Responses Using MHC Class I and II Tetramers

Poluektov¹,

Daftarian

Delcommenne³

2020

Preprint

View full text Add to dashboard Cite

AbstractThe success of SARS-CoV-2 (CoV-2) vaccines is measured by their ability to mount immune memory responses that are long-lasting. To achieve this goal, it is important to identify surrogates of immune protection, namely, CoV-2 MHC Class I and II immunodominant pieces/epitopes and methodologies to measure them. Here, we present results of flow cytometry-based MHC Class I and II QuickSwitch™ platforms for assessing SARS-CoV-2 peptide binding affinities to various human alleles as well as the H-2 Kb mouse allele. Multiple SARS-CoV-2 potential MHC binders were screened and validated by QuickSwitch testing. While several predicted peptides with acceptable theoretical Kd showed poor MHC occupancies, fourteen MHC class II and a few MHC class I peptides showed promiscuity in that they bind with multiple MHC molecule types. With the peptide exchange generated MHC tetramers, scientists can assess CD4+ and CD8+ immune responses to these different MHC/peptide complexes. Results obtained with several SARS-CoV-2 MHC class I and II peptides are included and discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

Assessment of SARS-CoV-2 Specific CD4(+) and CD8 (+) T Cell Responses Using MHC Class I and II Tetramers

Poluektov¹,

Daftarian

Delcommenne³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Accurate recognition of vaccines by antigen-presenting cells (APCs) and their efficient presentation to adaptive immune cells is critical to activating immune responses. Therefore, MHC I/II binding score, immunogenicity, antigenicity, and IFN-g inducing ability are key components that require optimal screening during the screening process of immunodominant epitopes (48)(49)(50). Herein, to ensure the PP13138R vaccine's accuracy and effectiveness, we employed a rigorous evaluation process that involved analyzing the vaccine's structure and properties, including the construction of the secondary, tertiary, tertiary structure, and recombinant plasmid.…”

Section: B C Amentioning

confidence: 99%

A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation

Jiang,

Han,

Liu

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionThe Bacillus Calmette-Guérin (BCG) vaccine, currently used against tuberculosis (TB), exhibits inconsistent efficacy, highlighting the need for more potent TB vaccines.Materials and methodsIn this study, we employed reverse vaccinology techniques to develop a promising multi-epitope vaccine (MEV) candidate, called PP13138R, for TB prevention. PP13138R comprises 34 epitopes, including B-cell, cytotoxic T lymphocyte, and helper T lymphocyte epitopes. Using bioinformatics and immunoinformatics tools, we assessed the physicochemical properties, structural features, and immunological characteristics of PP13138R.ResultsThe vaccine candidate demonstrated excellent antigenicity, immunogenicity, and solubility without any signs of toxicity or sensitization. In silico analyses revealed that PP13138R interacts strongly with Toll-like receptor 2 and 4, stimulating innate and adaptive immune cells to produce abundant antigen-specific antibodies and cytokines. In vitro experiments further supported the efficacy of PP13138R by significantly increasing the population of IFN-γ+ T lymphocytes and the production of IFN-γ, TNF-α, IL-6, and IL-10 cytokines in active tuberculosis patients, latent tuberculosis infection individuals, and healthy controls, revealing the immunological characteristics and compare the immune responses elicited by the PP13138R vaccine across different stages of Mycobacterium tuberculosis infection.ConclusionThese findings highlight the potential of PP13138R as a promising MEV candidate, characterized by favorable antigenicity, immunogenicity, and solubility, without any toxicity or sensitization.

show abstract

Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers

Poluektov¹,

George

Daftarian

et al. 2021

Vaccine

View full text Add to dashboard Cite

In Silico-Guided Sequence Modification of Epitopes in Cancer Vaccine Development

Cited by 4 publications

References 19 publications

Assessment of SARS-CoV-2 Specific CD4(+) and CD8 (+) T Cell Responses Using MHC Class I and II Tetramers

Assessment of SARS-CoV-2 Specific CD4(+) and CD8 (+) T Cell Responses Using MHC Class I and II Tetramers

A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation

Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers

Contact Info

Product

Resources

About